Stephanie Davis
Stock Analyst at Barclays
(0.83)
# 3,910
Out of 4,966 analysts
95
Total ratings
35.29%
Success rate
-110.67%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $181.64 | +1.85% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $37.88 | +18.80% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $18.07 | -72.33% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $67.94 | +10.39% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.48 | +27.74% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.35 | +37.93% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $9.65 | +96.89% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $291.61 | -0.55% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $25.90 | -7.34% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $148.78 | -10.61% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $32.59 | +77.97% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.66 | +12.78% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $277.99 | -10.43% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $31.66 | -8.40% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.73 | +339.84% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $23.67 | +43.64% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $269.20 | -13.45% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.39 | +401.47% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $89.33 | -14.92% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $181.64
Upside: +1.85%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $37.88
Upside: +18.80%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $18.07
Upside: -72.33%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $67.94
Upside: +10.39%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.48
Upside: +27.74%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.35
Upside: +37.93%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $9.65
Upside: +96.89%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $291.61
Upside: -0.55%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $25.90
Upside: -7.34%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $148.78
Upside: -10.61%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $32.59
Upside: +77.97%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.66
Upside: +12.78%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $277.99
Upside: -10.43%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $31.66
Upside: -8.40%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.73
Upside: +339.84%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $23.67
Upside: +43.64%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $269.20
Upside: -13.45%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.39
Upside: +401.47%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $89.33
Upside: -14.92%